Navigation

Explore our research

Pharma-Innovation - Patent 2 (Innova-P2)

Innova P2 banner

Innova-P2 is a 3-year Collaborative Project with a total budget of 728,640 Euro.

Project Summary

One-third of all human deaths (18 million every year) are from diseases that could have been prevented, cured or treated. Hundreds of millions more people suffer from these diseases, while the lives of their families are shattered by severe illness and premature deaths. Most of these cases occur among poor people in poor countries, often due to diseases that have been almost eliminated in the developed world, creating a disease burden which perpetuates their poverty.

But not only do 200 million people not have access to existing essential medicines which could alleviate their conditions. Currently, “neglected diseases”, which account for 90% of the global disease burden, receive only 10% of all medical research funds worldwide. Of the 1556 new drugs approved between 1975 and 2004, only 18 were for tropical diseases which affect millions of people.

Under the global TRIPs agreement, inventors of new drugs can obtain a 20-year global monopoly, but this regime prices most new drugs beyond the reach of the global poor. The existing system offers few incentives for the pharmaceutical development of medicines to address the real global disease burden, when more profit can be made from me-too drugs for hair loss.

Thomas Pogge recently co-authored a book on the Health Impact Fund – a proposal to create an alternative system funded by international governments, where pharmaceutical innovators could choose to register new products and then make these available at cost in order to receive a 10 year reward based on the assessment of the drug’s impact on the global disease burden. Innova-P2 is specifically designed to work along these lines and finalise the suggested IPR reform plan.

The inaugural meeting of the project took place in Oslo, 26-27 August 2008, hosted by the Centre for the Study of Mind in Nature, University of Oslo.

View Project Brochure (.pdf 820KB)

Project Aims

  • Advance knowledge and ethical insight into reform plans for the current Intellectual Property Rights (IPR) system.
  • Finalise the existing plan to amend the current IPR system in the area of pharmaceutical innovation.
  • Provide a reality check and obtain support for the new system from the world’s two most powerful developing/emerging country actors (India and China).
  • Promote urgent policy developments on IPR by forging a consensus for the new system and providing a policy action plan.

The Innova-P2 Consortium

Project Lead

Prof Thomas Pogge, Centre for Professional Ethics, University of Central Lancashire, Preston, UK
Thomas Pogge on Ted.com

 

Project Staff

Prof Thomas Pogge, Dr Miltos Ladikas, Julie Cook Lucas, (Project Co-ordinators) Centre for Professional Ethics, University of Central Lancashire, Preston, UK

Partners

Prof Arjun Sengupta, Dr Nagesh Kumar, Dr Sachin Chaturvedi, Research and Information System for Developing Countries, New Delhi, India

Prof Zhiqian Gao, Dr Lifeng Guo, Dr Zhe Li, Chinese Academy of Science and Technology for Development, Ministry of Science and Technology, Beijing, China

Prof Peter Singer, Prof Doris Schroeder, Centre for Applied Philosophy and Public Ethics,University of Melbourne, Australia

Prof. Jon Pedersen, FAFO, Oslo, Norway

Prof Fatima Alvarez Castillo, Department of Social Sciences, University of the Philippines Manila

Professor Lynn Frewer, Dr David Coles, Wageningen University, the Netherlands

External Advisers

Prof. Joseph Stiglitz Professor of Economics, Columbia University Nobel Laureate for Economics, 2001 Senior Vice-President and Chief Economist World Bank, 1997-2000

Dr. Tikki Pang WHO Director for Research Policy & Cooperation Former Professor of Biomedical Sciences, University of Malaya, Kuala Lumpur, Malaysia

Dr. Klaus Leisinger President and CEO of the Novartis Foundation for Sustainable Development and Professor of Development Sociology, University of Basel, Basel, Switzerland

Mr. Roger Chennells Legal Consultant, Stellenbosch, South Africa; specialism: IPR and Human Rights in Africa

Dr. Matthew Rimmer Senior Lecturer, Australian National University, College of Law; specialism: Intellectual Property Law

Dr. James Orbinski Prof of Medicine, University of Toronto Ex-President, Medecins Sans Frontieres Co-founder of Drugs for Neglected Diseases Initiative and Dignitas International

Dr. Gorik Ooms Former Director, Medecins Sans Frontieres, Belgium

Funders

Innova-P2 is a 3-year Collaborative Project with a total budget of 728,640 Euro, funded by the European Community's Seventh Framework Programme under grant agreement 217665.

Project funded by the Science in Society Programme.

Timeline

1 June 2008 - 31 May 2011.

High Level Interactive Foresight

INNOVA-P2: Delphi High Level Expert Group Survey (.doc 163KB)

 

Project Output and Deliverables

  • Intellectual Property Rights Reform Plans (Deliverable 1.1 .pdf 219KB) : Doris Schroeder and Peter Singer

  • Prudential Reasons for IPR Reform (Deliverable D1.2 .pdf 397KB) : Doris Schroeder and Peter Singer

  • Ethical Reasons for Intellectual Property Rights Reform (Deliverable 1.3 .pdf 320KB) : Peter Singer and Doris Schroeder

  • Cambridge Quarterly of Healthcare Ethics
    Symposium: Access to Life-Saving Medicines and Intellectual Property Rights (Deliverable D1.4 .pdf 14KB) : Prof. Doris Schroeder (Ed)

  • Innova-P2 Project Brochure (Deliverable D4.4 .pdf 820KB)

  • Study on Metrics and Distribution Mechanisms; Pharma Innovation for Low-Income Populations (Deliverable D2.1 .pdf 331) : Chinese Academy of Science and Technology for Development

  • D2.2 (.pdf 534KB) IPR Reform: Policy Suggestion for China-India Traditional Medicine Health Impact Initiative

  • The Health Impact Fund and Protective Measures (Deliverable 3.1 .pdf 430KB) : Dr Krishna Ravi Srinivas

  • Alignment of Innova-P2 goals with related Indian and Chinese WTO-work (Deliverable 3.2 .pdf 227KB) : Dr Krishna Ravi Srinivas

  • D3.3 (.pdf 741KB) Common Policy Grounds Between India and China on HIF

  • DELPHI FORESIGHT ANALYSIS (Deliverable 4.5 .pdf 1.2MB): Dr David Coles and Professor Lynn J. Frewer

Related Publications

Pogge, T.  World Poverty and Human Rights: Cosmopolitan Responsibilities and Reforms, second, expanded edition (Cambridge: Polity Press 2008); German translation by Jürgen Müller: Weltarmut und Menschenrechte (Berlin: de Gruyter 2011); Chinese translation by Li Shaomeng (Beijing: Commercial Press 2010). Chapter 9 
www.amazon.co.uk/World-Poverty-Human-Rights-Thomas/dp/074564144X/ref=sr_1_1?ie=UTF8&s=books&qid=1268131374&sr=8-1

Pogge, T., Rimmer, M. & Rubenstein, K. (eds) Incentives for Global Public Health: Patent Law and Access to Essential Medicines (Cambridge: Cambridge University Press 2010). 
www.cambridge.org/us/catalogue/catalogue.asp?isbn=9780521116565

Pogge, T. “The Health Impact Fund and Its Justification by Appeal to Human Rights” in Journal of Social Philosophy 40/4 (2009), 542–569. 
www3.interscience.wiley.com/journal/123197227/abstract?CRETRY=1&SRETRY=0

Pogge, T. “Health Care Reform that Works for the U.S. and for the World’s Poor” in Global Health Governance 2/2 (2009), available at http://ghgj.org/Pogge_Health%20Care%20Reform.pdf

Pogge, T. “The Health Impact Fund: Boosting Innovation Without Obstructing Free Access,” in Cambridge Quarterly of Healthcare Ethics 18/1 (Winter 2009), 78-86. 
journals.cambridge.org/action/displayIssue?jid=CQH&volumeId=18&issueId=01

Pogge, T. & Schroeder, D. “Why We Need A New Approach to Pharmaceutical Innovation – A Pragmatic Answer to a Moral Question”, in: Marc Noppen and Marleen Wynants (eds.) In Sickness and Health – The Future of Medicine, Brussels: Vrije Universiteit Brussel Press, 2009, p.197-213    

L.J. Frewer, et al., The use of Delphi methodology in agrifood policy development: Some lessons learned, Technol. Forecast. Soc. Change (2011), doi:10.1016/j.techfore.2011.05.005

Non-academic writings

“Globale medizinische Gerechtigkeit,” conversation with Thomas Mündle, Die Furche 48 (28 November 2008), 7. 

 “Geen aalmoezen geven, maar verantwoordelijkheid nemen,” interview with Aagje Ieven, Tijdschrift voor Mensenrechten 6/1 (2008), 4-6. 

Project Meetings

Project Launch

The inaugural meeting of the project took place in Oslo, 26-27 August 2008, hosted by the Centre for the Study of Mind in Nature, University of Oslo

Innova Oslo agenda (.doc 38KB)

Workshop on Alternate Patent Regime and Access to Health, Beijing, China, May 2009

On 25-26 May 2009, project research partners RIS (Research and Information System for Developing Countries) and CASTED (Chinese Academy of Science and Technology for Development) held a Workshop on Alternate Patent Regime and Access to Health in Beijing, China. The meeting was attended by a range of experts, together with Miltos Ladikas of the Innova-P2 co-ordination team. The workshop outlined directions for the project’s future research

Innova Beijing Agenda May 2009 (.doc 55KB)

Project Meeting August 2009, Beijing: Developing a plan to amend the intellectual property rights regime for pharmaceutical innovation

In August 2009, the whole project group was hosted by CASTED in Beijing to discuss a wide range of issues relating to access to medicines (pricing, distribution and protective mechanisms, health care structures, etc) along with progress on project deliverables. A number of external experts from China, India, the UK and Canada joined the group to provide feedback and present their thoughts on the project’s aims and deliverables.

The group also discussed Traditional Medicines and the possibilities for commercial development globally, and worked to develop consensus towards the idea of a regional application of IPR reform plans focusing on Traditional Medicines.

Innova Beijing draft agenda August (.doc 231KB) | Presentations (Login required)

Pharmaceutical Innovation and Access to Life-Saving Medicines, Innova-P2 project group in Melbourne, March 2010

Programme (.pdf 509KB)
Internal Project Meeting Agenda, Melbourne, March 2010 (.pdf 78KB)

Following the public events on 24-25 March, Innova partner CAPPE at the University of Melbourne hosted the project group for a meeting on 26th March. External advisors and experts from South Africa, Kenya, Canada and the WHO provided feedback on the recent project reports. The group discussed practical implementation issues around the HIF and received a summary of the recent Delphi study into perceptions of the HIF with a view to undertaking further quantitative research.

The Health Impact Fund – An Innovation in Global Health, April 2011, European Parliament, Brussels

This dissemination event took place at the European Parliament targeting policy making communities in Europe. The keynote speech was made by the EU Commissioner for Development Dr Pielbags who showed keen interest in the work of the project and suggested further detailed discussions on HIF within the framework of the EU’s development policy. Representation in this meeting included European policymakers, pharma industry, NGOs and a number of developing country ministerial officials.

Programme (.pdf 131KB)

International Conference on Equity and Access to Medicine; Role of Innovation and Institutions, 12 -13 May 2011, New Delhi

The conference was opened by Dr Kalam, former President of India, a globally respected figure in the S&T sector. It included a wide range of representation in high-level policymaking as well as Indian industry and NGO representation (see Programme). The project's work received wide approval and the HIF was confirmed as a means to increase access to medicines in the region. The full conference proceedings will be published as an edited book by Cambridge University Press.

Programme (.pdf 98KB)

Further Information

For information about the project, please contact: Julie Cook Lucas, Centre for Professional Ethics, Brook Building 317, University of Central Lancashire, Preston, PR1 2HE, UK (email: JMLucas@uclan.ac.uk).

The inaugural meeting of the project took place in Oslo, 26-27 August 2008, hosted by the Centre for the Study of Mind in Nature, University of Oslo.

LEGAL NOTICE
The views expressed in this website are the sole responsibility of the author and do not necessarily reflect the views of the European Commission.